PLAT and Stroke: Thrombolytic therapy (eg, r-tPA), which was approved by the State Food and Drug Administration of China in 2001, was administered to <1% of potentially eligible cases in the present study, compared with 3.0%–8.5% reported in the USA20 and 1.6% reported by the Chinese National Stroke Registry (CNSR) in 2011.21